# US 2016/0252512 A1 · Composition for diagnosing pancreatic cancer and method for diagnosing pancreatic cancer using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0252512 A1
- Document ID: US20160252512A1
- Status: Published application
- Kind: A1
- Application number: 14/901,157
- Filed: 2014-10-31
- Published: 2016-09-01
- Earliest claimed: 2013-10-31
- Assignees: SK Telecom Co., Ltd.; Seoul National University R&Db Foundation
- Applicants: SK Telecom Co., Ltd.; Seoul National University R&Db Foundation
- Inventors: Sangjo HAN; Yonghwan CHOI; Sung Gon YI; Taegyun YUN; Junghyun NAMKUNG; Youngsoo KIM; Taesung PARK; Jin-Young JANG
- Web page: https://patentgrep.com/patent/US20160252512A1

## CPC

- G01N 33/57525: of the liver or pancreas
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/158: Expression markers
- G01N 2333/705: Assays involving receptors, cell surface antigens or cell surface determinants
- G01N 2333/91188: transferring nitrogenous groups (2.6)
- G01N 2333/924: acting on glycosyl compounds (3.2)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

A composition, for diagnosing the possibility of onset of pancreatic cancer including an agent measuring the expression level of marker protein of diagnosing the possibility of onset of pancreatic cancer, or mRNA expression level of a gene encoding the protein, a kit including the composition, and a method of diagnosing pancreatic cancer using the maker are provided. The diagnostic markers of pancreatic cancer in accordance with the present disclosure are useful for predicting or diagnosing the onset, the possibility of onset, and the severity of pancreatic cancer in an early stage, and are also applied to a study on the tumorigenesis of pancreatic cancer. In addition, the diagnosis method of the present invention allows for the convenient detection of pancreatic cancer in a non-invasive manner in a sample such as blood.

## Claims

### Claim 1

A composition for diagnosing pancreatic cancer, comprising an agent for measuring a protein expression level of ABAT (4-aminobutyrate aminotransferase; GenBank Accession No: NP_001120920.1) protein, or a mRNA expression level of a gene coding for the ABAT protein.

### Claim 2 (depends on 1)

The composition for diagnosing pancreatic cancer of claim 1, further comprising an agent for measuring a protein expression level of CA19-9 protein, or a mRNA expression level of a gene coding for CA19-9 protein.

### Claim 3 (depends on 1)

The composition for diagnosing pancreatic cancer of claim 1, further comprising an agent for measuring a protein expression level of CHI3L1 (Chitinase-3-like protein 1 precursor; GenBank Accession No: NP_001267.2), or a mRNA expression level of a gene coding for CHI3L1 protein.

### Claim 4 (depends on 3)

The composition for diagnosing pancreatic cancer of claim 3, further comprising an agent for measuring a protein expression level of CA19-9 protein, or a mRNA expression level of a gene coding for CA19-9 protein.

### Claim 5 (depends on 1)

The composition for diagnosing pancreatic cancer of claim 1, wherein the agent for measuring a protein expression level comprises an antibody, an oligopeptide, a ligand, a PNA (peptide nucleic acid) or an aptamer, all of which can specifically bind to the protein.

### Claim 6 (depends on 1)

The composition for diagnosing pancreatic cancer of claim 1, wherein the agent for measuring an mRNA expression level comprises a primer, a probe, or an antisense nucleotide, all of which specifically bind to an mRNA of the gene encoding the marker protein.

### Claim 7 (depends on 1)

A kit for diagnosing pancreatic cancer, comprising the composition of claim 1.

### Claim 8 (depends on 7)

The kit of claim 7, wherein the kit is an RT-PCR (reverse transcription polymerase chain reaction) kit, a DNA chip kit, an ELISA (enzyme linked immunosorbent assay) kit, a protein chip kit, a rapid kit, or an MRM (multiple reaction monitoring) kit.

### Claim 9

A method for diagnosing pancreatic cancer, comprising:
(a) obtaining a sample from a subject to be diagnosed for the onset of pancreatic cancer;
(b) measuring a protein expression level of ABAT protein (4-aminobutyrate aminotransferase; GenBank Accession No: NP_001120920.1) or a mRNA expression level of a gene encoding ABAT protein;
(c) comparing the protein expression level of ABAT protein or the mRNA expression level of a gene encoding ABAT protein, with those of corresponding normal control; and
(d) determining that the possibility of onset of pancreatic cancer is high, when the protein expression level of ABAT protein or the mRNA expression level of a gene encoding ABAT protein is higher than those of corresponding normal control in the subject, based on the comparison result in (c) step.

### Claim 10 (depends on 9)

The method for diagnosing pancreatic cancer of claim 9, comprising:
(a) obtaining a sample from a subject to be diagnosed for the onset of pancreatic cancer;
(b) measuring a protein expression level of each ABAT protein (4-aminobutyrate aminotransferase; GenBank Accession No: NP_001120920.1) and CA19-9 protein or a mRNA expression level of each gene encoding ABAT protein and CA19-9 protein;
(c) comparing the protein expression level of each ABAT protein and CA19-9 protein or the mRNA expression level of each gene encoding ABAT protein and CA19-9 protein, with those of corresponding normal control; and
(d) determining that the possibility of onset of pancreatic cancer is high, when the protein expression level of ABAT protein or the mRNA expression level of a gene encoding ABAT protein is higher than those of corresponding normal control in the subject, and the protein expression level of CA19-9 protein or the mRNA expression level of a gene encoding CA19-9 protein is higher than those of corresponding normal control, based on the comparison result in (c) step.

### Claim 11 (depends on 9)

The method for diagnosing pancreatic cancer of claim 9, comprising:
(a) obtaining a sample from a subject to be diagnosed for the onset of pancreatic cancer;
(b) measuring a protein expression level of ABAT (4-aminobutyrate aminotransferase; GenBank Accession No: NP_001120920.1) protein and CHI3L1 (Chitinase-3-like protein 1 precursor; GenBank Accession No: NP_001267.2) protein or a mRNA expression level of each gene encoding ABAT protein and CHI3L1 protein;
(c) comparing the protein expression level of each ABAT protein and CHI3L1 protein or the mRNA expression level of each gene encoding ABAT protein and CHI3L1 protein, with those of corresponding normal control; and
(d) determining that the possibility of onset of pancreatic cancer is high, when the protein expression level of ABAT protein or the mRNA expression level of a gene encoding ABAT protein is higher than those of corresponding normal control in the subject, and the protein expression level of CHI3L1 protein or the mRNA expression level of a gene encoding CHI3L1 protein is lower than those of corresponding normal control, based on the comparison result in (c) step.

### Claim 12 (depends on 9)

The method for diagnosing pancreatic cancer of claim 9, comprising:
(a) obtaining a sample from a subject to be diagnosed for the onset of pancreatic cancer;
(b) measuring a protein expression level of each ABAT protein, CHI3L1 protein and CA19-9 protein or a mRNA expression level of each gene encoding ABAT protein, CHI3L1 protein and CA19-9 protein;
(c) comparing the protein expression levels of each ABAT protein, CHI3L1 protein and CA19-9 protein or a mRNA expression level of each gene encoding ABAT protein, CHI3L1 protein and CA19-9 protein, with those of corresponding normal control; and
(d) determining that the possibility of onset of pancreatic cancer is high, when the expression level of ABAT protein or the mRNA expression level of a gene encoding ABAT protein is higher than those of corresponding normal control in the subject,
the protein expression level of CHI3L1 protein or the mRNA expression level of a gene encoding CHI3L1 protein is lower than those of corresponding normal control, and
the protein expression level of CA19-9 protein or the mRNA expression level of a gene encoding CA19-9 protein is higher than those of corresponding normal control, based on the comparison result in (c) step.

### Claim 13 (depends on 9)

The method of claim 9, wherein the sample is blood, serum or plasma.

### Claim 14 (depends on 9)

The method of claim 9, wherein the measuring of protein expression level utilizes antibodies, oligopeptides, ligands, PNAs (peptide nucleic acids), or aptamers that can specifically bind to corresponding marker proteins, respectively.

### Claim 15 (depends on 9)

The method of claim 9, wherein the measuring or comparing of protein expression level is carried out by using at least one selected from the group consisting of protein chip assay, immunoassay, ligand binding assay, MALDI-TOF (Matrix Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry), SELDI-TOF (Surface Enhanced Laser Desorption/Ionization Time of Flight Mass Spectrometry), radioimmunoassay, radial immunodiffusion, Ouchterlony immunodiffusion, Rocket immunoelectrophoresis, immunohistostaining, complement fixation test, 2-D electrophoresis, liquid chromatography-mass spectrometry (LC-MS), liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS), Western blotting, and ELISA (enzyme-linked immunosorbentassay).

### Claim 16 (depends on 9)

The method of claim 9, wherein the measuring of mRNA expression level is carried out by using reverse transcription polymerase chain reaction (RT-PCR), competitive RT-PCR, real-time RT-PCR, RNase protection assay, Northern blotting, or DNA chip.
